Published in AIDS on June 19, 2010
The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 3.96
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A (2011) 2.39
Systemic effects of inflammation on health during chronic HIV infection. Immunity (2013) 2.34
Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis (2014) 2.28
Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis (2014) 2.26
Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol (2013) 2.01
Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis (2012) 1.91
HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis (2012) 1.83
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr (2010) 1.70
Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J (2011) 1.64
Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis (2013) 1.36
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev (2013) 1.31
Relationship between neck circumference and cardiometabolic parameters in HIV-infected and non-HIV-infected adults. Diabetes Care (2011) 1.26
Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS (2014) 1.19
Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med (2011) 1.14
HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol (2012) 1.10
Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev (2013) 1.08
Progression of carotid intima-media thickness and coronary artery calcium over 6 years in an HIV-infected cohort. J Acquir Immune Defic Syndr (2013) 1.08
Effects of smoking on non-AIDS-related morbidity in HIV-infected patients. Clin Infect Dis (2013) 1.01
Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect Dis (2013) 0.99
HIV infection and cardiovascular disease in women. J Am Heart Assoc (2014) 0.97
Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study. BMC Infect Dis (2013) 0.97
Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS (2014) 0.96
Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS (2014) 0.94
Epidemiology of ischaemic heart disease in sub-Saharan Africa. Cardiovasc J Afr (2013) 0.94
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS One (2014) 0.92
HIV and aging: emerging research issues. Curr Opin HIV AIDS (2014) 0.91
Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis (2016) 0.90
Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retroviruses (2014) 0.88
Coagulation and morbidity in treated HIV infection. Thromb Res (2014) 0.87
Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review. Virulence (2013) 0.87
Pro-Inflammatory Markers in Relation to Cardiovascular Disease in HIV Infection. A Systematic Review. PLoS One (2016) 0.87
Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients. J Acquir Immune Defic Syndr (2013) 0.87
Inflammation, immune activation, and cardiovascular disease in HIV. AIDS (2016) 0.87
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med (2016) 0.86
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis (2013) 0.85
Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep (2013) 0.85
HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol (2012) 0.84
A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy. BMC Infect Dis (2013) 0.84
Tobacco use and cessation in HIV-infected individuals. Clin Chest Med (2013) 0.84
Dynamics of regulatory T-cells during pregnancy: effect of HIV infection and correlations with other immune parameters. PLoS One (2011) 0.83
Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe. HIV AIDS (Auckl) (2015) 0.83
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J Infect Dis (2016) 0.82
Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy. AIDS Res Hum Retroviruses (2012) 0.81
Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag (2015) 0.81
Vitamin D Levels and Markers of Inflammation and Metabolism in HIV-Infected Individuals on Suppressive Antiretroviral Therapy. AIDS Res Hum Retroviruses (2015) 0.80
Elevated Soluble CD14 and Lower D-Dimer Are Associated With Cigarette Smoking and Heavy Episodic Alcohol Use in Persons Living With HIV. J Acquir Immune Defic Syndr (2015) 0.80
Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. HIV Med (2015) 0.79
The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis (2014) 0.79
Cardiovascular Disease in Blacks with HIV/AIDS in the United States: A Systematic Review of the Literature. Open AIDS J (2012) 0.79
Chronic HIV disease and activation of the coagulation system. Thromb Res (2013) 0.78
An association between adiposity and serum levels of macrophage inflammatory protein-1α and soluble CD14 in HIV-infected adults: results from a cross-sectional study. Antivir Ther (2013) 0.77
Immune activation and regulation in simian immunodeficiency virus-Plasmodium fragile-coinfected rhesus macaques. J Virol (2013) 0.77
Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study. BMJ Open (2013) 0.76
D-Dimer Levels and Traditional Risk Factors Are Associated With Incident Hypertension Among HIV-Infected Individuals Initiating Antiretroviral Therapy in Uganda. J Acquir Immune Defic Syndr (2016) 0.75
Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study. PLoS One (2015) 0.75
Association of markers of hemostasis with death in HIV-infected women. J Acquir Immune Defic Syndr (2014) 0.75
Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study. Infect Dis Ther (2016) 0.75
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One (2013) 0.75
Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV. J Am Heart Assoc (2016) 0.75
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS One (2015) 0.75
Role of high-sensitivity C-reactive protein measurements in HIV patients. Indian J Sex Transm Dis (2016) 0.75
HIV positive youth who are perinatally infected have impaired endothelial function. AIDS (2017) 0.75
C-Reactive Protein as an Independent Cardiovascular Risk Predictor in HIV+ Patients: A Focused Review of Published Studies. J Clin Med Res (2017) 0.75
Inflammation Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It? J Acquir Immune Defic Syndr (2017) 0.75
The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV. PLoS One (2017) 0.75
HIV-1-Associated Atherosclerosis: Unraveling the Missing Link. J Am Coll Cardiol (2017) 0.75
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 23.07
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation (2000) 7.37
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation (1998) 4.89
C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation (1998) 4.80
Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med (2008) 4.55
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol (1989) 3.00
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation (1999) 2.65
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol (2007) 2.19
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. Eur Heart J (2008) 1.68
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol (2009) 1.67
CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int (2007) 1.58
The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol (2009) 1.55
Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr (2009) 1.41
Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS (2009) 1.39
HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS (2009) 1.35
HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci U S A (2001) 1.33
CD14(high)CD16(+) rather than CD14(low)CD16(+) monocytes correlate with disease progression in chronic HIV-infected patients. J Acquir Immune Defic Syndr (2009) 1.29
Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol (2009) 1.27
Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest (2009) 1.22
Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr (2009) 1.11
Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation (1994) 1.11
A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods (2003) 1.09
Vascular cell adhesion molecule-1 expression in endothelial cells exposed to physiological coronary wall shear stresses. J Biomech Eng (2009) 0.98
Tissue inhibitor of metalloproteinase-1 is an early marker of acute endothelial dysfunction in a rodent model of venous oxidative injury. Ann Vasc Surg (2009) 0.89
Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation (1994) 0.88
The role of the Framingham risk score to predict the presence of subclinical coronary atherosclerosis in patients with HIV infection. J Acquir Immune Defic Syndr (2009) 0.85
Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease. Eur J Clin Invest (2006) 0.85
Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol (2002) 0.85
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One (2012) 3.69
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis (2011) 2.88
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol (2008) 2.85
Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr (2005) 2.63
Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood (2008) 2.27
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome. Blood (2012) 2.03
In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest (2005) 1.96
HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A (2008) 1.95
Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr (2003) 1.82
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood (2010) 1.66
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol (2012) 1.45
Cutting edge: L-selectin (CD62L) expression distinguishes small resting memory CD4+ T cells that preferentially respond to recall antigen. J Immunol (2003) 1.42
A1C underestimates glycemia in HIV infection. Diabetes Care (2009) 1.41
Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS (2009) 1.39
Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia. J Infect Dis (2009) 1.38
CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol (2011) 1.37
Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis (2013) 1.36
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther (2011) 1.32
Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS (2011) 1.30
d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin Immunol (2010) 1.26
Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood (2013) 1.24
Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS (2014) 1.19
CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J Virol (2011) 1.19
HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. J Virol (2013) 1.17
Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther (2005) 1.17
Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism (2002) 1.17
IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa. Blood (2012) 1.14
Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood (2010) 1.13
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS (2011) 1.13
Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164. J Infect Dis (2012) 1.12
Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci U S A (2002) 1.12
Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood (2012) 1.12
Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev (2013) 1.08
Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism (2010) 1.03
Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. AIDS (2014) 1.03
Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood (2010) 1.03
Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome. J Appl Physiol (1985) (2003) 1.02
CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis (2007) 1.02
Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr (2002) 1.02
Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr (2005) 1.01
Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab (2004) 1.01
Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther (2013) 1.01
Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS (2007) 1.01
Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells. Arthritis Res Ther (2012) 1.00
Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood (2011) 1.00
The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS One (2010) 1.00
Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr (2008) 1.00
HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. Virology (2005) 0.99
Negative regulation of human U6 snRNA promoter by p38 kinase through Oct-1. Gene (2012) 0.99
CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis (2008) 0.99
Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr (2008) 0.98
Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy. J Acquir Immune Defic Syndr (2006) 0.98
Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit (2004) 0.98
IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3. Eur J Immunol (2008) 0.98
Coronary artery abnormalities in Hyper-IgE syndrome. J Clin Immunol (2011) 0.95
Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis (2013) 0.93
Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab (2005) 0.93
Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance. Blood (2011) 0.91
Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS (2009) 0.91
Cerebrospinal fluid HIV-1 compartmentalization in a patient with AIDS and acute varicella-zoster virus meningomyeloradiculitis. Clin Infect Dis (2013) 0.90
Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments. J Infect Dis (2011) 0.90
Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol (2012) 0.89
Increased prevalence of albuminuria in HIV-infected adults with diabetes. PLoS One (2011) 0.89
The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One (2013) 0.88
Retinoic acid and liver X receptor agonist synergistically inhibit HIV infection in CD4+ T cells by up-regulating ABCA1-mediated cholesterol efflux. Lipids Health Dis (2012) 0.88
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. AIDS (2015) 0.87
Abnormal cardiac strain in children and young adults with HIV acquired in early life. J Am Soc Echocardiogr (2012) 0.87